Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting
Keywords: کارسینوم نفوذی قلبی عروقی; Gene expression; Breast cancer; Endocrine therapy; Tamoxifen; Progression-free survival; DCIS; ductal carcinoma in situ; EMC; Rotterdam Dutch cohort; ER; estrogen receptor; ER+; estrogen receptor-positive; ERBB2; HER2/ERBB2 mRNA level; ESR1; estrogen rece